Royalty Pharma (RPRX) said Wednesday that it has agreed to provide Biogen (BIIB) with up to $250 million in research and development funding for drug candidate litifilimab to potentially treat systemic lupus erythematosus and cutaneous lupus erythematosus.
The company said it will provide the funding over six quarters in exchange for regulatory milestones and mid-single digit royalties on annual worldwide sales.
Litifilimab is currently in phase 3 trials, with results expected between 2026 and 2027, Royalty Pharma said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。